新しい研究が小児がんに対する免疫療法の可能性を拓く(New study paves way for immunotherapies tailored for childhood cancers)

ad

2025-01-20 カロリンスカ研究所(KI)

カロリンスカ研究所とアストリッド・リンドグレーン小児病院の研究では、子どもの免疫システムががんに対してどのように反応するかを解明し、年齢や腫瘍の種類による差異を特定しました。研究は191名の小児がん患者の免疫応答を分析し、腫瘍特性に加え免疫特性を考慮する「精密医療」の新しい次元を提案しました。子どもの腫瘍は炎症性が低く、免疫反応が弱い場合が多いため、既存の免疫療法(例: チェックポイント阻害薬)が効果的でないことが示されました。この知見は、子ども向けに特化した免疫療法の開発に道を開く可能性があります。

<関連情報>

固形腫瘍を持つ小児におけるシステムレベルの免疫モニタリングによる精密医療の実現 Systems-level immunomonitoring in children with solid tumors to enable precision medicine

Qi Chen∙ Binbin Zhao∙ Ziyang Tan∙ … ∙ Per Kogner∙ Linda Ljungblad∙ Petter Brodin
Cell  Published:January 20, 2025
DOI:https://doi.org/10.1016/j.cell.2024.12.014

Graphical abstract

新しい研究が小児がんに対する免疫療法の可能性を拓く(New study paves way for immunotherapies tailored for childhood cancers)

Highlights

•ISAC is a population-based pediatric pan-cancer cohort of 191 children
•Systemic immunity varies by tumor type and age and differs from that in healthy children
•Tumor mutation rates vary widely and track with immune cell infiltration
•Expanded CD8+ T cell responses are rare in children but regulated like those of adult cells

Summary

Cancer is the leading cause of death from disease in children. Survival depends not only on surgery, cytostatic drugs, and radiation but also on systemic immune responses. Factors influencing these immune responses in children of different ages and tumor types are unknown. Novel immunotherapies can enhance anti-tumor immune responses, but few children have benefited, and markers of effective responses are lacking. Here, we present a systems-level analysis of immune responses in 191 children within a population-based cohort with diverse tumors and reveal that age and tumor type shape immune responses differently. Systemic inflammation and cytotoxic T cell responses correlate with tumor mutation rates and immune cell infiltration. Clonally expanded T cell responses are rarely detected in blood or tumors at diagnosis but are sometimes elicited during treatment. Expanded T cells are similarly regulated in children and adults with more immunogenic cancers. This research aims to facilitate the development of precision immunotherapies for children with cancer.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました